ID

37902

Description

A Study of Avastin (Bevacizumab) in Combination With Gemcitabine and Carboplatin as First Line Treatment in Patients With Triple Negative Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01201265

Link

https://clinicaltrials.gov/show/NCT01201265

Keywords

Versions (1)
  1. 8/29/19 8/29/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

August 29, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Breast Cancer NCT01201265

English

Eligibility Breast Cancer NCT01201265

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
female patients, >/= 18 years of age
Description

Gender | Age

Data type

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0001779
metastatic breast cancer
Description

Secondary malignant neoplasm of female breast

Data type

boolean

Alias
UMLS CUI [1]
C0346993
estrogen receptor- , progesterone- and her2-negative disease
Description

Disease Estrogen receptor negative Progesterone receptor negative HER2 Negative

Data type

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0279756
UMLS CUI [1,3]
C0279766
UMLS CUI [1,4]
C2348908
treatment-naïve for metastatic breast cancer
Description

Therapy naive Secondary malignant neoplasm of female breast

Data type

boolean

Alias
UMLS CUI [1,1]
C0919936
UMLS CUI [1,2]
C0346993
eastern cooperative oncology group (ecog) performance status 0-1
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
adequate hematological, renal and liver function
Description

Hematologic function | Renal function | Liver function

Data type

boolean

Alias
UMLS CUI [1]
C0221130
UMLS CUI [2]
C0232804
UMLS CUI [3]
C0232741
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior first line treatment for metastatic breast cancer
Description

First line treatment Previous Secondary malignant neoplasm of female breast

Data type

boolean

Alias
UMLS CUI [1,1]
C1708063
UMLS CUI [1,2]
C0205156
UMLS CUI [1,3]
C0346993
cns metastasis
Description

CNS metastases

Data type

boolean

Alias
UMLS CUI [1]
C0686377
uncontrolled hypertension (> 170/95 mmhg)
Description

Uncontrolled hypertension | Blood pressure determination

Data type

boolean

Alias
UMLS CUI [1]
C1868885
UMLS CUI [2]
C0005824
evidence of bleeding diathesis, coagulopathy or hemorrhage at baseline
Description

Bleeding tendency | Blood Coagulation Disorder | Hemorrhage

Data type

boolean

Alias
UMLS CUI [1]
C1458140
UMLS CUI [2]
C0005779
UMLS CUI [3]
C0019080
history of other malignant disease within past 3 years, except for curatively treated basal cell carcinoma of the skin and carcinoma in situ of the cervix
Description

Cancer Other | Exception Curative treatment Basal cell carcinoma | Exception Curative treatment Carcinoma in situ of uterine cervix

Data type

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C1273390
UMLS CUI [2,3]
C0007117
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C1273390
UMLS CUI [3,3]
C0851140
prior therapy with gemcitabine or carboplatin in the metastatic setting. patients having received gemcitabine or carboplatin as part of adjuvant therapy are eligible, if recurrence was first documented >6 months after the last exposure to the drug(s)
Description

Prior Therapy | gemcitabine | Carboplatin | Neoplasm Metastasis | Adjuvant therapy

Data type

boolean

Alias
UMLS CUI [1]
C1514463
UMLS CUI [2]
C0045093
UMLS CUI [3]
C0079083
UMLS CUI [4]
C0027627
UMLS CUI [5]
C0677850
requirement of chronic use of immunosuppressive agents
Description

Requirement Immunosuppressive Agents chronic

Data type

boolean

Alias
UMLS CUI [1,1]
C1514873
UMLS CUI [1,2]
C0021081
UMLS CUI [1,3]
C0205191
hiv, hepatitis b or hepatitis c infection
Description

HIV Infection | Hepatitis B | Hepatitis C

Data type

boolean

Alias
UMLS CUI [1]
C0019693
UMLS CUI [2]
C0019163
UMLS CUI [3]
C0019196
Back to the top of the page

Similar models

Eligibility Breast Cancer NCT01201265

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Gender | Age
Item
female patients, >/= 18 years of age
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Secondary malignant neoplasm of female breast
Item
metastatic breast cancer
boolean
C0346993 (UMLS CUI [1])
Disease Estrogen receptor negative Progesterone receptor negative HER2 Negative
Item
estrogen receptor- , progesterone- and her2-negative disease
boolean
C0012634 (UMLS CUI [1,1])
C0279756 (UMLS CUI [1,2])
C0279766 (UMLS CUI [1,3])
C2348908 (UMLS CUI [1,4])
Therapy naive Secondary malignant neoplasm of female breast
Item
treatment-naïve for metastatic breast cancer
boolean
C0919936 (UMLS CUI [1,1])
C0346993 (UMLS CUI [1,2])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status 0-1
boolean
C1520224 (UMLS CUI [1])
Hematologic function | Renal function | Liver function
Item
adequate hematological, renal and liver function
boolean
C0221130 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
First line treatment Previous Secondary malignant neoplasm of female breast
Item
prior first line treatment for metastatic breast cancer
boolean
C1708063 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0346993 (UMLS CUI [1,3])
CNS metastases
Item
cns metastasis
boolean
C0686377 (UMLS CUI [1])
Uncontrolled hypertension | Blood pressure determination
Item
uncontrolled hypertension (> 170/95 mmhg)
boolean
C1868885 (UMLS CUI [1])
C0005824 (UMLS CUI [2])
Bleeding tendency | Blood Coagulation Disorder | Hemorrhage
Item
evidence of bleeding diathesis, coagulopathy or hemorrhage at baseline
boolean
C1458140 (UMLS CUI [1])
C0005779 (UMLS CUI [2])
C0019080 (UMLS CUI [3])
Cancer Other | Exception Curative treatment Basal cell carcinoma | Exception Curative treatment Carcinoma in situ of uterine cervix
Item
history of other malignant disease within past 3 years, except for curatively treated basal cell carcinoma of the skin and carcinoma in situ of the cervix
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C1273390 (UMLS CUI [2,2])
C0007117 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C1273390 (UMLS CUI [3,2])
C0851140 (UMLS CUI [3,3])
Prior Therapy | gemcitabine | Carboplatin | Neoplasm Metastasis | Adjuvant therapy
Item
prior therapy with gemcitabine or carboplatin in the metastatic setting. patients having received gemcitabine or carboplatin as part of adjuvant therapy are eligible, if recurrence was first documented >6 months after the last exposure to the drug(s)
boolean
C1514463 (UMLS CUI [1])
C0045093 (UMLS CUI [2])
C0079083 (UMLS CUI [3])
C0027627 (UMLS CUI [4])
C0677850 (UMLS CUI [5])
Requirement Immunosuppressive Agents chronic
Item
requirement of chronic use of immunosuppressive agents
boolean
C1514873 (UMLS CUI [1,1])
C0021081 (UMLS CUI [1,2])
C0205191 (UMLS CUI [1,3])
HIV Infection | Hepatitis B | Hepatitis C
Item
hiv, hepatitis b or hepatitis c infection
boolean
C0019693 (UMLS CUI [1])
C0019163 (UMLS CUI [2])
C0019196 (UMLS CUI [3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial